Validation of an Artificial Intelligence Enabled Diagnostic Support Software (ArtiQ.Spiro) in Primary Care Spirometry Datasets - a Retrospective Analysis

NCT ID: NCT05648227

Last Updated: 2025-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-01

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A retrospective study to evaluate the diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK primary care spirometry datasets.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a retrospective analysis of existing clinical datasets with consecutive spirometry collected in a primary care setting in the UK. Individual patient data will be included if the individual meets the study protocol eligibility criteria.

Clinical datasets will be de-identified (name, date of birth, address, postcode, occupation GP, ethnicity, medications data removed). Individuals will be identified by a study ID number. The de-identified datasets will contain the minimum information needed for spirometry and ArtiQ.Spiro - namely age, smoking history, height, weight, primary respiratory symptom - and the deidentified data exported from the primary care spirometry software.

ArtiQ.Spiro Evaluation (Index Tests for Diagnosis and Quality):

A deidentified dataset will be provided to a machine learning analyst who will apply the machine learning algorithm of ArtiQ.Spiro. For each individual, the algorithm will produce a preferred diagnosis (highest probability diagnostic category) (Index Test for Diagnosis) and an assessment of spirometry quality (Acceptable, Usable, Not Acceptable/Usable) (Index Test for Quality). No clinical information outside of the spirometry dataset nor reference standard data will be made available to the analyst.

Reference Standard for Diagnosis:

The clinical dataset, together with available primary care records and secondary care records, will be used by the senior members of the direct clinical care team (Consultants in Respiratory Medicine with an interest in integrated respiratory care) to provide a reference standard for diagnosis. For each individual, two consultants will provide a diagnosis independently and blinded to the index test (ArtiQ.Spiro) output. If there is agreement, this diagnosis will be taken as the reference standard for diagnosis for the individual. If there is no agreement, a third consultant outside the direct clinical care team will be provided with the same information (but deidentified) to act as final arbitrator.

Reference Standard for Quality:

A deidentified dataset will be provided to a specialist respiratory physiologist. He/she will grade the quality of each spirometric session according to the official American Thoracic Society / European Respiratory Society 2019 Technical Statement for Standardization of Spirometry. For each patient, the quality of the spirometry session will be graded according to one of three categories: Acceptable, Usable, Not Acceptable/Usable. This will act as the reference standard for quality. The respiratory physiologists will be blinded to the output from the Index Test (ArtiQ.Spiro). The respiratory physiologists will also record time taken to evaluate the dataset.

Data Analysis:

Data analysis will be performed by the research team who will be independent to the direct clinical care team and the respiratory physiologists who will be providing the reference standards for diagnosis and quality respectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult aged 18 years or over
* At least one of the following respiratory symptoms: cough, wheeze, shortness of breath, reduced exercise tolerance
* Spirometry performed for clinical purposes in a non-hospital lung function setting (such as a community clinic, a GP practice, or at home)
* Spirometry was supervised by a doctor or non-medical allied health professional

Exclusion Criteria

* Aged 17 or under
* No respiratory symptoms
* Spirometry performed for pre-operative assessment
* Spirometry performed exclusively as part of a research study
* Spirometry performed at home without supervision.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Hillingdon Hospitals NHS Foundation Trust

OTHER_GOV

Sponsor Role collaborator

University of Leicester

OTHER

Sponsor Role collaborator

Southern Health NHS Foundation Trust

OTHER

Sponsor Role collaborator

Imperial College London

OTHER

Sponsor Role collaborator

Queen Mary University of London

OTHER

Sponsor Role collaborator

King's College London

OTHER

Sponsor Role collaborator

Papworth Hospital NHS Foundation Trust

OTHER_GOV

Sponsor Role collaborator

King's College Hospital NHS Trust

OTHER

Sponsor Role collaborator

Royal Brompton & Harefield NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William Man, FRCP

Role: PRINCIPAL_INVESTIGATOR

Royal Brompton & Harefield Hospitals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Harefield Hospital

Middlesex, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

314058

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.